title: [A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus].
abstract: We report a case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus. A 66-year-old man was diagnosed with hepatocellular carcinoma with Vp3 by abdominal enhanced CT. He underwent a complete tumor resection and following interferon and 5-FU combined intra-arterial chemotherapy as an adjuvant setting. The histological findings were consistent with combined hepatocellular and cholangiocarcinoma. At 9 months after the surgery, lymph node metastases were detected. Then we started an oral fluoropyrimidine anticancer agent S-1, because the recurrence was suspected to be originated from the cholangiocarcinoma component. Thereafter, sustained partial remission was achieved. In case of combined hepatocellular and cholangiocarcinoma, we need to create a treatment strategy against characteristics of both components.
authors.affiliation: Department of Surgery, Graduate School of Medicine, Osaka University.
authors.forename: Hisanori
authors.initials: H
authors.lastname: Hatano
authors.forename: Shogo
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nagano
authors.forename: Akira
authors.initials: A
authors.lastname: Tomokuni
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Tomimaru
authors.forename: Masahiro
authors.initials: M
authors.lastname: Murakami
authors.forename: Shigeru
authors.initials: S
authors.lastname: Marubashi
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Eguchi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takeda
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tanemura
authors.forename: Kenichi
authors.initials: K
authors.lastname: Wakasa
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Doki
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001650:Bile Duct Neoplasms / Q000473:pathology / Q000628:therapy*; D001653:Bile Ducts, Intrahepatic; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D018281:Cholangiocarcinoma / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005472:Fluorouracil / Q000008:administration & dosage; D006498:Hepatectomy; D006801:Humans; D007372:Interferons / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D010094:Oxonic Acid / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D007372:Interferons; D005472:Fluorouracil